Human Umbilical Cord blood monocytes, rescue brain cells from hypoxic-ischemic injury:

https://www.biorxiv.org/content/10.1101/670794v1.full

Finally I found publication about CD14 cells in cord blood from Duke!

here Duke study about CD14 +

Cd14 in cord blood

they found potential not in perepheric blood !!!so not all cd14 are equal :

« Gene expression microarray analysis demonstrated that compared to PB-CD14 monocytes, CB-CD14 monocytes over-expressed several secreted proteins with potential to protect neurons. Differential expression of five candidate effector molecules, chitinase 3-like protein-1, inhibin-A, interleukin-10, matrix metalloproteinase-9 and thrombospondin-1, were confirmed by western blotting, and immunofluorescence. These findings suggest that CD14 monocytes are a critical cell-type when treating HI with CB-MNC. »

« intravenously injected CB-MNC products [55] do not need to reach the brain in order to promote repair of stroke or other HI brain injury. Instead, cell products

reaching the lungs or spleen may induce endogenous cells to produce soluble factors or activated

cells that go to the brain and mediate repair [56-58]. Future studies investigating the

biodistribution of CB monocytes will determine the most effective route and dose for

administration.

In summary, monocytes in CB, but not PB, protect brain neurons from death and reduce glial

activation following HI insult in an in vitro OGD model. Soluble factors released from CB

monocytes contribute to this protection. We have identified secreted proteins enriched in CBCD14+ monocytes compared to PB monocytes that may play a role in neuroprotection and repair.

This work enables future detailed study of the mechanism of neuroprotection and development

of mechanism-based release assays for CB products, and formulation of new strategies for using

CB monocytes as therapeutic agents in treatment of HI-induced brain injuries. »

LOW-LEVEL LIGHT THERAPY (LLLT) or photobiomodulation.

Lideur mondiale dans étude de LLLT:

Michael R Hamblin Ph.D.

Associate Professor

Department of Dermatology

Harvard Medical School

BAR 414

Wellman Center for Photomedicine

Massachusetts General Hospital

40 Blossom Street

Boston MA 02114

USA

Member of Affiliated Faculty of Harvard-MIT Division of Health Sciences and

Technology

Tel 617-726-6182

Fax 617-726-6643

e-mail hamblin@helix.mgh.harvard.edu

“Low level laser (light) therapy (LLLT) also known as photobiomodulation (PBM) therapy has been practiced for almost fifty years, and hundreds of positive clinical trials and thousands of laboratory studies have been published. Despite these impressive accomplishments LLLT has still not reached the stage of acceptance by mainstream medicine. The reasons for this were discussed at a recent Optical Society of America (OSA) Incubator meeting in Washington DC in 2014. Uncertainty about mechanisms was highlighted, and this paper will describe the current thinking. To drive LLLT towards mainstream medicine, we need better guidelines with standardized protocols and consistent parameters. Studies should be published in higher impact scientific and medical journals. Companies should avoid false promises and deceptive marketing, and physicians should receive a clearly defined return on investment with insurance reimbursement.”

Source:

https://www.researchgate.net/publication/281708244_Low_level_laser_light_therapy_and_photobiomodulation_The_path_forward

Anglais:

http://photobiology.info/Hamblin.html

Russe:

https://flyclipart.com/ru-hamblin

He adviced me to use this model:

https://joovv.com/products/joovv-light?variant=39356431694

Looking at the brain as a tissue….

« There are several degrees of damage to the brain tissue, and the most severe one is necrosis because the tissue is fully dead, there’s nothing there. In the instance where we have necrotic tissue, there is nothing we can do. But in the surrounding tissue, there might be tissue that is not fully dead, that is damaged. In this tissue, we have metabolic dysfunction. The cells in this area have sufficient oxygen supply to stay alive, but they don’t have the full energy needed for the full activation. This is where hyperbaric oxygen can help. The challenge is to be able to demonstrate this. »

Good article interesting interview with dr Efrati 😉 yes my son doctor :

https://www.neurologylive.com/clinical-focus/hyperbaric-oxygen-therapy-offers-hope-post-stroke-cognition-issues

No comments

Just for anybody’s who wants to comment on my blog : I am not confirming ANY comments on it I had too much spam messages and I don’t have time to see all comments which is good or spam … so I delate every day ALL COMMENTS send me

Sorry for your inconvenience but it’s like this

If you want to contact me ( not spam) send me mail:

svetpanuta@gmail.com

And I will see if it’s really professional mail or just a spam ( haw to create my blog and not about nerologie – all spam I put in garbage !!!)

My blog is free I am not gaining money from it I don’t have time for useless comments.

Thanks for understanding

I am just not confirming ANY comments on my blog

Just for anybody’s who wants to comment on my blog : I am not confirming ANY comments on it I had too much spam messages and I don’t have time to see all comments which is good or spam … so I delate every day ALL COMMENTS send me

Sorry for your inconvenience but it’s like this

HBOT 2019 Speaker Videos HBOT 2019

I invite you to see all 38 presentations :

HBOT 2019 Speaker Videos

HBOT 2019

As Ted Fogarty posted this I suppose we can all share

On link you can find all speakers from last dr Harch symposium 2019!!!!!

Latest research of Hbot

About Cannabis

About LLLT

And much more

I am shearing but I can’t put my head on everybody’s shoulders

Just try to see yourself!!!!

https://www.youtube.com/playlist?list=PLTOK_IVnJp5lUfDeSn5fVeb9hdpa2a_1g

HBOT 2019 Speaker Videos

https://www.youtube.com/playlist?list=PLTOK_IVnJp5lUfDeSn5fVeb9hdpa2a_1g

Pons clinics :

Answering on many requests:

Working clinics using PoNS technology in Russia and Canada:

RUSSIA

Moscow

“Rehaline” – Rehabilitation Center- Director Dr. Evgeny Bugorsky,

rehaline.ru

+1 495 763 0734,

medsyst@hotmail.com

Topics: Multiple sclerosis, Traumatic Brain Injury, Stroke, Parkinson’s disease and etc

Sankt Petersburg,

Odoevskogo str., 28

Dr. Lavrentiy Tsoj

phone: +7 (812) 603-70-10

admin@newday-clinic.ru

Topics: Multiple sclerosis, Traumatic Brain Injury, Stroke, Parkinson’s disease and etc.

Stavropol

Shapkovskaya St., 100

Drs. Pavel & YuliaTimchenko

email: tp@neuro-clinic.life

WhatsUp: +7 961-452-1800

https://neuro-clinic.life/

Topics: Pediatric neurology, Autism, Crebral Palsy, ADD/ADHD

CANADA

Montreal, QC

Mazaltarim Marcel, MSc, Director

1140 Beaumont,

T.M.R., Montreal, QC H3P 3E5

514-481-7867

info@neuromtl.com

neuromtl.com

Topics: Multiple sclerosis, Traumatic Brain Injury, Stroke, Parkinson’s disease

Surrey, BC

Surrey Neuroplasticity Clinic

Suite 204, 13737 96 Ave.

Surrey, BC, V3V 0C6

P: 1-604-424-8280

F: 1-888-597-8564

Effect of hyperbaric oxygen therapy on chronic neurocognitive deficits of post-traumatic brain injury patients: retrospective analysis

HBOT – What does it do, and how does it treat medical conditions :

The latest seminar by the best experts on healing the brain from Israel, June 2019

https://youtu.be/dyQHztkfiNg

Prof Shai Efrati is the leader in the field of treatment utilising HBOT and achieving what DRUGS can’t.

Israeli Researchers Assaf Harofe find Hyperbaric Oxygen therapy was associated with significant cognitive improvements.

And if we are talking about previous studies with 1.2 ATA on 21% inhaled oxygen (ie, air) cannot be regarded as an inert or sham control!!!!

« In addition to objective evaluations, there are inherent ethical and logistic difficulties in handling the sham control in HBOT trials. HBOT includes two active ingredients: pressure and oxygen. Pressure is needed to increase plasma oxygen, but the pressure change alone may also have significant cellular effects. Additionally, the greatest effect of pressure is in human tissues that are under tight autoregulation pressure control, such as the brain, where the intracranial pressure is normally 0.0092–0.0197 atm.23 24 To generate a pressure sensation, the chamber pressure must be 1.2 ATA or higher. However, such a change in environmental pressure (from 1 ATA to 1.2 ATA) and subsequent tissue oxygenation (with an increase of tissue oxygenation by at least 50%) has a significant biological effect. Thus, sham therapy in previous studies using 1.2 ATA on 21% inhaled oxygen (ie, air) cannot be regarded as an inert or sham control but rather as a lower dose of the active ingredient.4 20 In regards to a possible effect of vasoconstriction of the large blood vessels induced by hyperbaric oxygen—it has been well established that the tissues are saturated by hyperoxia and do not suffer from hypoxia, as the vasoconstriction effect is compensated by increased plasma oxygen content and microvascular blood flow.

Any increase in pressure, even with reduced oxygen percentage, cannot serve as a true placebo, but rather as a low dosage of the active ingredient, further supporting the need for objective data gathered from large cohorts of patients suffering from PCS and treated by HBOT.

Source: https://bmjopen.bmj.com/content/8/9/e023387